• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Joyce Liu, MD, MPH

Publications

  • Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA.Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.Oncotarget. 2014 May 15;5(9):2678-87.
    24798692
  • Liu JF, Konstantinopoulos PA, Matulonis UA.PARP inhibitors in ovarian cancer: Current status and future promise.Gynecol Oncol. 2014 May;133(2):362-369.
    24607283
  • Liu JF, Cannistra SA.Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.J Clin Oncol. 2014 May 1;32(13):1287-9.
    24637996
  • Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, Etemadmoghadam D, Bowtell DD, Drapkin R.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Cancer Res. 2014 Feb 15;74(4):1141-52.
    24366882
  • Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, Drapkin R, Hahn WC.In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene.Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1102-7.
    24385586
  • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.PLoS ONE. 2013;8(11):e80023.
    24265793
  • Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6.
    24085845
  • Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA.Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.Gynecol Oncol. 2013 Aug 13.
    23954902
  • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Eur J Cancer. 2013 Sep;49(14):2972-8.
    23810467
  • Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, , Matulonis UA.Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome.Clin Cancer Res. 2012 Oct 15;18(20):5806-5815.
    22912389
  • Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, Hirsch MS, Mesirov JP, Drapkin R, Root DE, Lo J, Fogal V, Ruoslahti E, Hahn WC, Bhatia SN.Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.Sci Transl Med. 2012 Aug 15;4(147):147ra112.
    22896676
  • Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S.Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.Gynecol Oncol. 2012 Jul;126(1):41-6.
    22487536
  • Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF.An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.Cancer Cell. 2010 Mar 16;17(3):298-310.
    20227043
  • Liu JF, Hirsch MS, Lee H, Matulonis UA.Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.Gynecol Oncol. 2009 Dec;115(3):401-6.
    19796795